Abstract:Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that, for the cell migration and invasion assay data shown in Fig. 3A, C, E and G on p. 1843, a number of overlapping data sections were identified such that data which were intended to show the results from differently performed experiments had apparently been derived from the same original sources; moreover, these overlaps were featured in different alignments relative to their matching partners. In addition, other errors had been made during the process of compiling the figures; for example, the authors had overlooked indicating that the protein data shown in Fig. 1F were for β‑catenin. In view of the number of overlapping data panels that were identified in Fig. 3, the Editor of International Journal of Molecular Medicine has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [ International Journal of Molecular Medicine 45: 1838‑1850, 2020; DOI: 10.3892/ijmm.2020.4543].

Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Erratum: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance”

Corrigendum: Receptor of advanced glycation end products deficiency attenuates cisplatin-induced acute nephrotoxicity by inhibiting apoptosis, inflammation and restoring fatty acid oxidation

Correction to: Cypripedin, a phenanthrenequinone from Dendrobium densiflorum, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Correction: Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles

[Retracted] Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing

Correction: Corrigendum: Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma

Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]